Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service bronchoscopy & lung nodule cases in Maine: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 6% on average (216 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 9 | 332 | 39% |
| 2020 | 5 | 321 | 46% |
| 2021 | 5 | 311 | 51% |
| 2022 | 4 | 301 | 56% |
| 2023 | 2 | 185 | 59% |
| 2024 | 3 | 224 | 62% |
| 2025 from claims | – | 309 250–363 | 63% |
| 2026 forecast | – | 317 248–398 | 63% |
| 2027 forecast | – | 319 236–422 | 64% |
| 2028 forecast | – | 321 227–443 | 64% |
| 2029 forecast | – | 323 219–463 | 65% |
| 2030 forecast | – | 325 213–482 | 65% |
EBUS, navigational and robotic bronchoscopy, endobronchial valves, VATS lobectomy. Professional codes (what the surgeon bills): CPT 31652, 31653, 31628, 31647, 32663.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in Maine; 2 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 4% inpatient hospital, 96% hospital outpatient.
| Forecast, Medicare FFS | Inpatient | Hospital outpatient |
|---|---|---|
| 2026 · ~320 | ~10 | ~310 |
| 2027 · ~320 | ~9 | ~310 |
| 2028 · ~320 | ~8 | ~310 |
The forecast’s cases at the projected mix.
If the trend since 2022 holds, slowing as it goes, by 2028: inpatient hospital about 3% (4% in 2025), hospital outpatient about 97% (96% in 2025).
CMS rule changes ahead
From CMS’s OPPS/ASC final rules; the move measured on CMS’s claim summary, nationally, code by code. Medicare only, and not in the projected bars.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Pennsylvania | 75 | 5,343+1.2%/yr | +1.2%/yr | 4.0 | 0% | 7,380 in 2030+5.5%/yr |
| New York | 82 | 4,973+1.9%/yr | +1.9%/yr | 2.8 | 0% | 7,320 in 2030+6.6%/yr |
| Massachusetts | 48 | 3,057+5.5%/yr | +5.5%/yr | 3.3 | 0% | 4,980 in 2030+8.5%/yr |
| New Jersey | 36 | 2,104+9.9%/yr | +9.9%/yr | 2.0 | 0% | 4,020 in 2030+11%/yr |
| Connecticut | 12 | 1,083+3.5%/yr | +3.5%/yr | 3.3 | 0% | 2,100 in 2030+12%/yr |
| New Hampshire | 8 | 422+0.3%/yr | +0.3%/yr | 1.9 | 0% | 790 in 2030+11%/yr |
| Vermont | 4 | 192+6.8%/yr | +6.8%/yr | 1.7 | 0% | 560 in 2030+20%/yr |
| Rhode Island | 4 | 147+4.9%/yr | +4.9%/yr | 1.6 | 0% | 310 in 2030+13%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Colonoscopy & upper endoscopy | 77 | 12,348−6.2%/yr | −6.2%/yr | 81.70.6× | 16% | 12,100 in 2030−0.4%/yr |
| ERCP & endoscopic ultrasound | 6 | 387−3.6%/yr | −3.6%/yr | 2.50.7× | 0% | 440 in 2030+2.2%/yr |
Bronchoscopy & lung nodule in every state, and its device makers · Every procedure market in Maine · Every state · Compare with Pennsylvania
Boston Scientific leads with 65% of company spending on these surgeons in 2025, +62 pts on 2024.
In 2025, 6 companies reported engagement with Maine’s surgeons worth $2,443 in consulting, speaking, meals and travel tied to these products, about $814 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 11 clearances and approvals in the category, 4 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.